Following a third quarter print and clinical update from Aurinia Pharmaceuticals (NASDAQ:AUPH) on its pivotal study in lupus nephritis (LN), Canaccord analyst Neil Maruoka continues to be largely bullish on this biotech player. The company’s LN asset voclosporin between strong efficacy and a standout safety profile could attract some global attention for a partnering opportunity that has secured an eager bull in Maruoka.
Aurinia Has Canaccord Captivated with Voclosporin Prospects
